PublishedJournal ArticleThis is the author accepted manuscript. The final version is available from Nature Publishing Group via the DOI in this record.n/aO.C. is funded by a postdoctoral research fellowship by the University of Exeter Medical School
Background: Surrogate endpoints (i.e., intermediate endpoints intended to predict for patient-cente...
Background Opinions differ about the extent to which intervention research should and can directly a...
Objectives: Licensing of, and coverage decisions on, new therapies should rely on evidence from pati...
We propose a three step framework for the evaluation of surrogate endpoints for health policy decisi...
The efficacy of medicines, medical devices, and other health technologies should be proved in trials...
The efficacy of medicines, medical devices, and other health technologies should be proved in trials...
The efficacy of medicines, medical devices, and other health technologies should be proved in trials...
In recent years, the cost of drug development has increased the demands on efficiency in the selecti...
Background. Surrogate endpoints (i.e., intermediate endpoints intended to predict for patient-center...
Background: Surrogate endpoints (i.e., intermediate endpoints intended to predict for patient-center...
The efficacy of health technologies, medicines and medical devices should be demonstrated in trails ...
Surrogate endpoints predict the occurrence and timing of a clinical endpoint of interest (CEI). Subs...
PublishedJournal ArticleResearch Support, Non-U.S. Gov'tReviewThis is the author accepted manuscript...
Pivotal trials on morbidity and mortality (eg, in coronary heart disease, AIDS, cancer) are not only...
Objectives: Licensing of, and coverage decisions on, new therapies should rely on evidence from pati...
Background: Surrogate endpoints (i.e., intermediate endpoints intended to predict for patient-cente...
Background Opinions differ about the extent to which intervention research should and can directly a...
Objectives: Licensing of, and coverage decisions on, new therapies should rely on evidence from pati...
We propose a three step framework for the evaluation of surrogate endpoints for health policy decisi...
The efficacy of medicines, medical devices, and other health technologies should be proved in trials...
The efficacy of medicines, medical devices, and other health technologies should be proved in trials...
The efficacy of medicines, medical devices, and other health technologies should be proved in trials...
In recent years, the cost of drug development has increased the demands on efficiency in the selecti...
Background. Surrogate endpoints (i.e., intermediate endpoints intended to predict for patient-center...
Background: Surrogate endpoints (i.e., intermediate endpoints intended to predict for patient-center...
The efficacy of health technologies, medicines and medical devices should be demonstrated in trails ...
Surrogate endpoints predict the occurrence and timing of a clinical endpoint of interest (CEI). Subs...
PublishedJournal ArticleResearch Support, Non-U.S. Gov'tReviewThis is the author accepted manuscript...
Pivotal trials on morbidity and mortality (eg, in coronary heart disease, AIDS, cancer) are not only...
Objectives: Licensing of, and coverage decisions on, new therapies should rely on evidence from pati...
Background: Surrogate endpoints (i.e., intermediate endpoints intended to predict for patient-cente...
Background Opinions differ about the extent to which intervention research should and can directly a...
Objectives: Licensing of, and coverage decisions on, new therapies should rely on evidence from pati...